Erratum:  PTEN  deletion drives acute myeloid leukemia resistance to MEK inhibitors

Amanda M. Smith; Christine R.C. Zhang; Alexandre S. Cristino; John P. Grady; J. Lynn Fink; Andrew S. Moore

doi:10.18632/oncotarget.27402

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Errata:

Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors

PDF | How to cite

Oncotarget. 2020; 11:305-305. https://doi.org/10.18632/oncotarget.27402

Metrics: PDF 927 views | ?

Amanda M. Smith^1,4,*, Christine R.C. Zhang^1,4,*, Alexandre S. Cristino^1,6, John P. Grady^1,5, J. Lynn Fink¹ and Andrew S. Moore^1,2,3

¹ The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia
² Oncology Services Group, Queensland Children’s Hospital, South Brisbane, Australia
³ Child Health Research Centre, The University of Queensland, South Brisbane, Australia
⁴ Current address: Washington University in Saint Louis, Saint Louis, Missouri, United States of America
⁵ Current address: Garvan Institute of Medical Research, Darlinghurst, Australia
⁶ Current address: Griffith Institute for Drug Discovery, Brisbane Innovation Park, Nathan, Australia
^* These authors contributed equally to this work

Published: January 21, 2020

This article has been corrected: During production, the 4th affiliation was mistakenly added to the name of the last author, Dr. Andrew S. Moore. The proper affiliation information is shown below.

Amanda M. Smith^1,4,*, Christine R.C. Zhang^1,4,*, Alexandre S. Cristino^1,6, John P. Grady^1,5, J. Lynn Fink¹ and Andrew S. Moore^1,2,3

¹ The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia
² Oncology Services Group, Queensland Children’s Hospital, South Brisbane, Australia
³ Child Health Research Centre, The University of Queensland, South Brisbane, Australia
⁴ Current address: Washington University in Saint Louis, Saint Louis, Missouri, United States of America
⁵ Current address: Garvan Institute of Medical Research, Darlinghurst, Australia
⁶ Current address: Griffith Institute for Drug Discovery, Brisbane Innovation Park, Nathan, Australia
^* These authors contributed equally to this work

Original article: Oncotarget. 2019; 10:5755–5767. DOI: https://doi.org/10.18632/oncotarget.27206.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27402

Publication Alerts

Errata:

Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors